pressreleasebutton.jpg    calendar.jpg    Newspaper white.jpg    in thecommunitybutton.jpg

Click on the icon to jump down in the page




Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostate cancer (mCRPC) patient blood samples is predictive of therapeutic benefit. Previous work by the same team, reported in JAMA Oncology, demonstrated that nuclear localized AR-V7 protein in CTCs was predictive of a 76 percent reduction of risk of death for mCRPC patients who received taxane chemotherapy versus Androgen Receptor Signaling inhibitors (ARSi), Zytiga and Xtandi.

Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC). In addition to profiling genome wide copy number variation (CNV) from single cells, the authors also validated the ability to characterize the extent of genomic instability within individual CTCs. The study "Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis" published today in PLOS ONE utilizing the Epic Sciences "No Cell Left Behind" CTC platform.

Liquid Biopsy Biomarker Identifies Patients with Improved Response to PARP Inhibition in Metastatic Castrate Resistant Prostate Cancer

Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors (ARSi) compared to those treated with ARSi alone (overall response rate of 93 percent vs. 22 percent). PARP inhibitors are one of the largest classes of new cancer drugs in development and target a type of genomic instability associated with homologous recombination DNA repair deficiency (HRD).



EORTC 2016

November 29 - Dec 2, 2016 in Munich, Germany

World CDx Boston 2016

October 18-21, 2016 in Boston, Massachusetts

ESMO 2016

October 7-11, 2016 in Copenhagen, Denmark

Genomic Health to Market Epic Sciences’ AR-V7 Liquid Biopsy Test

NEW YORK (GenomeWeb) - Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

Test Aids Prostate Cancer Treatment

Wall Street Journal - Genomic Health will commercialize a new screening to influence choice of therapies

Guest Commentary: Back to cancer’s drawing board

By Murali Prahalad of Epic Sciences A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.



Join Epic At Relay For Life On August 15 and 16

Epic Sciences will be participating in the Relay for Life August 15 and 16 here in San Diego. Join us in honoring cancer survivors, remembering those we have lost and to raise funds for the American Cancer Society. Our tent will be on the marina side of the Embarcadero.

Celebrating an Epic Year of Service!

Our Epic Gives Back program is a key element of our work culture, and we strive to give back to the community as much as we can. Seeing that National Volunteer Week, which takes place April 12-18 this year, is about inspiring, recognizing and encouraging people to go out and engage others in their community, we are recognizing all our volunteer’s efforts the past year.

Epic Team Member, Laura Leitz, Wins Prostate Cancer Foundation Fundraising Award

Last week, the Prostate Cancer Foundation’s Vice President of Movember Initiatives presented a plaque to commemorate Laura Leitz, research assistant at Epic Sciences, for her commitment to Movember and fighting cancer.